{"disease":{"id":"dyslipidaemia","name":"dyslipidaemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT06834932","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01218204","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05129241","title":"Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector","phase":"","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06890169","title":"OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT04641299","title":"A Study of AZD8233 in Participants With Dyslipidemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05979428","title":"A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07497776","title":"Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"National Institute of Kidney Disease and Urology (NIKDU)","has_results":false},{"nct_id":"NCT07492264","title":"Evaluation of Food Supplementation in Subjects With Suboptimal Levels of LDL Cholesterol","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Cooper Consumer Health","has_results":false},{"nct_id":"NCT00903617","title":"Study to Test GSK256073 in Patients With Dyslipidemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07218900","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00783549","title":"A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06671405","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00808093","title":"Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06923956","title":"Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Humanis Saglık Anonim Sirketi","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}